Can a biologic clear the clogged airways of COPD?

NCT ID NCT07749001

Not yet recruiting Disease control Sponsor: Western University, Canada Source: ClinicalTrials.gov ↗

First seen Aug 06, 2026 · Last updated Aug 07, 2026 · Updated 1 time

Summary

This study tests whether mepolizumab, an injectable medication, can improve lung ventilation and reduce mucus plugs in adults with COPD who have elevated eosinophils. Participants receive mepolizumab every 4 weeks for 48 weeks and undergo MRI and CT scans along with breathing tests to measure changes. The goal is to see if this treatment can help clear airways and improve lung function.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: mepolizumab (Nucala) injection
What this could lead to: If successful, this could show that mepolizumab improves lung function and reduces mucus buildup in COPD patients, potentially guiding better treatment strategies.
What could go wrong: This is a small, early-phase study (36 participants) without a placebo group, so results may not be conclusive or generalizable. Possible side effects of mepolizumab include headache, injection site reactions, and rare allergic reactions.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for COPD (CHRONIC OBSTRUCTIVE PULMONARY DISEASE) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

chronic obstructive pulmonary disease COPD, severe early onset

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

COPD (CHRONIC OBSTRUCTIVE PULMONARY DISEASE)

More trials for these conditions

Other studies related to the condition(s) this trial covers.